• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Hydroxychloroquine in the prophylaxis of COVID 19: A survey of safety on the healthcare workers in India.羟氯喹预防新型冠状病毒肺炎：印度医护人员安全性调查
Perspect Clin Res. 2021 Jan-Mar;12(1):58-59. doi: 10.4103/picr.PICR_310_20. Epub 2021 Jan 19.
2
Waiting for Godot: A cross sectional survey based analysis of the hydroxychloroquine prophylaxis strategy against COVID-19 in India.《等待戈多》：基于横断面调查的印度羟氯喹预防新冠病毒策略分析
J Public Health Res. 2020 Dec 30;9(4):1888. doi: 10.4081/jphr.2020.1888. eCollection 2020 Oct 14.
3
Hydroxychloroquine as antiviral prophylaxis for exposed caregivers to Covid-19: An urgent appraisal is needed.羟氯喹作为暴露于新冠病毒的护理人员的抗病毒预防用药：需要紧急评估。
J Infect Public Health. 2020 Jun;13(6):865-867. doi: 10.1016/j.jiph.2020.05.005. Epub 2020 May 11.
4
Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?羟氯喹作为 COVID-19 的预防或治疗药物：证据说了什么？
Indian J Public Health. 2020 Jun;64(Supplement):S125-S127. doi: 10.4103/ijph.IJPH_496_20.
5
Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19.使用羟氯喹和干扰素 α-2b 预防 COVID-19。
Med Hypotheses. 2020 Nov;144:109802. doi: 10.1016/j.mehy.2020.109802. Epub 2020 May 20.
6
Hydroxychloroquine for prophylaxis and treatment of COVID-19 in health-care workers.羟氯喹用于医护人员预防和治疗新型冠状病毒肺炎
New Microbes New Infect. 2020 Nov;38:100813. doi: 10.1016/j.nmni.2020.100813. Epub 2020 Nov 12.
7
Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?在长期护理医院，COVID-19 的暴露后预防可否被视为疫情应对策略？
Int J Antimicrob Agents. 2020 Jun;55(6):105988. doi: 10.1016/j.ijantimicag.2020.105988. Epub 2020 Apr 17.
8
Side effects of hydroxychloroquine prophylaxis against COVID-19 in healthcare workers.医护人员使用羟氯喹预防新冠病毒病的副作用
Med J Armed Forces India. 2021 Jul;77(Suppl 2):S513-S514. doi: 10.1016/j.mjafi.2020.11.016. Epub 2021 Jul 26.
9
Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan.COVID-19 住院患者中阿奇霉素和羟氯喹的主动预防（ProPAC-COVID）：统计分析计划。
Trials. 2020 Oct 20;21(1):867. doi: 10.1186/s13063-020-04795-0.
10
COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020.2020 年法国长期接受羟氯喹治疗的类肉瘤病患者中的 COVID-19 病例。
Emerg Infect Dis. 2020 Oct;26(10):2513-2515. doi: 10.3201/eid2610.201816. Epub 2020 Jul 1.

引用本文的文献

1
Effectiveness of early pharmaceutical interventions in symptomatic COVID-19 patients: A randomized clinical trial.早期药物干预对有症状的COVID-19患者的有效性：一项随机临床试验。
Pak J Med Sci. 2024 May-Jun;40(5):800-810. doi: 10.12669/pjms.40.5.8757.
2
A Clinical Insight on New Discovered Molecules and Repurposed Drugs for the Treatment of COVID-19.关于新发现的用于治疗新冠肺炎的分子和重新利用药物的临床见解。
Vaccines (Basel). 2023 Feb 1;11(2):332. doi: 10.3390/vaccines11020332.

本文引用的文献

1
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.羟氯喹作为 COVID-19 暴露后预防的随机试验。
N Engl J Med. 2020 Aug 6;383(6):517-525. doi: 10.1056/NEJMoa2016638. Epub 2020 Jun 3.
2
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.羟氯喹治疗主要为轻症和中症的 2019 冠状病毒病患者：开放标签、随机对照试验。
BMJ. 2020 May 14;369:m1849. doi: 10.1136/bmj.m1849.
3
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].羟氯喹治疗中度新型冠状病毒肺炎患者的一项试点研究
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219. doi: 10.3785/j.issn.1008-9292.2020.03.03.
4
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.羟氯喹和阿奇霉素联合治疗 COVID-19 患者：法国马赛 1061 例回顾性分析。
Travel Med Infect Dis. 2020 May-Jun;35:101738. doi: 10.1016/j.tmaid.2020.101738. Epub 2020 May 5.
5
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.对于重症新冠病毒感染患者，没有证据表明羟氯喹和阿奇霉素联合使用能实现快速的抗病毒清除或带来临床益处。
Med Mal Infect. 2020 Jun;50(4):384. doi: 10.1016/j.medmal.2020.03.006. Epub 2020 Mar 30.
6
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
7
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.

Hydroxychloroquine in the prophylaxis of COVID 19: A survey of safety on the healthcare workers in India.

作者信息

Mukhopadhyay Sandip, Paul Suhrita, Samanta Basabdatta

机构信息

Department of Pharmacology, Burdwan Medical College, Burdwan, West Bengal, India.

Department of Principal, Burdwan Medical College, Burdwan, West Bengal, India.

出版信息

Perspect Clin Res. 2021 Jan-Mar;12(1):58-59. doi: 10.4103/picr.PICR_310_20. Epub 2021 Jan 19.

DOI:10.4103/picr.PICR_310_20
PMID:33816211
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8011517/
Abstract
摘要